Expect to see Valeant Pharmaceuticals International Inc. (NYSE: VRS, TSX: VRX) continue to expand in the skincare sector via M&A.

The company's latest move, the $360 million acquisition of Obagi Medical Products Inc. (Nasdaq: OMPI) - announced on March 20 - won't be its last, according to Laurie Little, vice president of investor relations.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.